TherapeuticsMD (TXMD) Earnings Analysis

TherapeuticsMD (TXMD) next reports earnings on 2026-08-17, consensus EPS -5.5 USD. Last quarter (2026-03-30) it missed with EPS -0.0535 USD vs 0.04 USD est (-233.8%). It has beaten estimates in 0/2 recent quarters (0%). Trailing P/E 131.17.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TXMD next report earnings?

Next earnings date2026-08-17
Consensus EPS estimate-5.5 USD
Revenue estimate0.02B

TXMD earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-30-0.0535 USD0.04 USD-233.8%Miss
2025-11-120.01313 USDn/an/an/a
2024-08-12-0.09 USD0.03 USD-400%Miss

Beat rate: 0/2 (0%) over reported quarters with consensus data.

TXMD valuation and analyst view

Trailing P/E131.17
Trailing EPS0.01547 USD
Price / book0.87
Dividend yield0.00%
Market cap0.02B
Analyst consensusBuy (4 buy / 3 hold / 1 sell)

Related research pages

Frequently asked questions

When is TherapeuticsMD (TXMD)'s next earnings date?

TherapeuticsMD is next scheduled to report on 2026-08-17, with a consensus EPS estimate of -5.5 USD and revenue estimate of 0.02B.

Did TXMD beat earnings last quarter?

In its 2026-03-30 report, TXMD posted EPS of -0.0535 USD versus a 0.04 USD estimate — a miss of 233.8%.

What is TXMD's earnings track record?

Over the last 2 reported quarters with consensus data, TXMD beat estimates 0 times (0%).

What is TXMD's current P/E ratio and EPS?

TXMD trades at a trailing P/E of 131.17 on trailing EPS of 0.015465698980473475 USD.

What do analysts rate TXMD?

Analyst consensus is "Buy" across 8 ratings (0 strong buy, 4 buy, 3 hold, 1 sell, 0 strong sell).